Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

@article{Sternberg1989MethotrexateVD,
  title={Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.},
  author={Cora N Sternberg and Alexandre Yagoda and Howard I. Scher and Robin Caird Watson and Nancy V Geller and Harry W. Herr and Michael J. Morse and Pramod G. Sogani and Jr E. Darracott Vaughan and Neil Harrison Bander},
  journal={Cancer},
  year={1989},
  volume={64 12},
  pages={
          2448-58
        }
}
Of 133 patients with advanced urothelial tract cancer given methotrexate (MTX), vinblastine (VBL), Adriamycin (ADR) (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (DDP) (M-VAC regimen), significant tumor regression occurred in 72% +/- 8% of 121 with transitional cell carcinoma (TCC) evaluable for response. Complete remission (CR) was achieved in 36% +/- 9% of patients, of whom 11% required the addition of surgical resection of residual disease. Although 68% of CR patients have… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 171 CITATIONS, ESTIMATED 39% COVERAGE

Nested Variant of Urothelial Carcinoma

  • Advances in urology
  • 2014
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Recent advances in medical therapy for metastatic urothelial cancer

  • International Journal of Clinical Oncology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

1992
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

Similar Papers

Loading similar papers…